破傷風治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Tetanus - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0948
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:94
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Tetanus – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Tetanus – Pipeline Review, H1 2020, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Tetanus – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 5, 7, 2, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tetanus – Overview
Tetanus – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tetanus – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tetanus – Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Biken Co Ltd
Biological E Ltd
BioNet- Asia Co Ltd
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
GC Pharma
GlaxoSmithKline Plc
KM Biologics Co Ltd
LG Chem Ltd
Novo Medi Sciences Pvt Ltd
NTxBio LLC
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi Pasteur SA
Seasons Healthcare Ltd
Serum Institute of India Ltd
Shantha Biotechnics Pvt Ltd
Sichuan ZehaTimes Pharmaceutical Co Ltd
Stablepharma Ltd
Yisheng Biopharma Co Ltd
Yuxi Jiuzhou Biological Technology Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd
Tetanus – Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetanus – Dormant Projects
Tetanus – Discontinued Products
Tetanus – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Tetanus, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
Tetanus - Pipeline by Beijing Tiantan Biological Products Co Ltd, H1 2020
Tetanus - Pipeline by Biken Co Ltd, H1 2020
Tetanus - Pipeline by Biological E Ltd, H1 2020
Tetanus - Pipeline by BioNet- Asia Co Ltd, H1 2020
Tetanus - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2020
Tetanus - Pipeline by Cadila Healthcare Ltd, H1 2020
Tetanus - Pipeline by CanSino Biologics Inc, H1 2020
Tetanus - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
Tetanus - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Tetanus - Pipeline by GC Pharma, H1 2020
Tetanus - Pipeline by GlaxoSmithKline Plc, H1 2020
Tetanus - Pipeline by KM Biologics Co Ltd, H1 2020
Tetanus - Pipeline by LG Chem Ltd, H1 2020
Tetanus - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
Tetanus - Pipeline by NTxBio LLC, H1 2020
Tetanus - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
Tetanus - Pipeline by Panacea Biotec Ltd, H1 2020
Tetanus - Pipeline by Sanofi Pasteur SA, H1 2020
Tetanus - Pipeline by Seasons Healthcare Ltd, H1 2020
Tetanus - Pipeline by Serum Institute of India Ltd, H1 2020
Tetanus - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2020
Tetanus - Pipeline by Sichuan ZehaTimes Pharmaceutical Co Ltd, H1 2020
Tetanus - Pipeline by Stablepharma Ltd, H1 2020
Tetanus - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
Tetanus - Pipeline by Yuxi Jiuzhou Biological Technology Co Ltd, H1 2020
Tetanus - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, H1 2020
Tetanus - Dormant Projects, H1 2020
Tetanus - Dormant Projects, H1 2020 (Contd..1), H1 2020
Tetanus - Discontinued Products, H1 2020

【掲載企業】

Beijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Biken Co Ltd
Biological E Ltd
BioNet- Asia Co Ltd
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
GC Pharma
GlaxoSmithKline Plc
KM Biologics Co Ltd
LG Chem Ltd
Novo Medi Sciences Pvt Ltd
NTxBio LLC
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi Pasteur SA
Seasons Healthcare Ltd
Serum Institute of India Ltd
Shantha Biotechnics Pvt Ltd
Sichuan ZehaTimes Pharmaceutical Co Ltd
Stablepharma Ltd
Yisheng Biopharma Co Ltd
Yuxi Jiuzhou Biological Technology Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[破傷風治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆